Insightful conversations with leading experts in the field of health care, medical research, policy, and more from the New England Journal of Medicine (NEJM). Each episode examines the many complexities found at the junction of medicine and society.
http://www.nejm.org/multimedia/audio-interview
NEJM Interview: Dr. Roy Perlis on esketamine as an option for treatment-resistant depression.
Dr. Roy Perlis is the director of the Center for Quantitative Health at Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Kim and Others. Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class. N Engl J Med 2019;381:1-4.